

# Evidence-Based Preventive Care Checklist for New Immigrants and Refugees

#### **REGION**

SHE	-SAH	ΔΡΔΝ	ΔFR	ICΔ

Name	Date					
Date of Arrival in Canada _		Language(s) spoken				
Country of Origin	Famil	y Supports_				
Settlement/Refugee Claima	nt Worker	Ref	iugee Claimant Hearing Date _			
	1 <sup>st</sup> Visit					
	Date:					
Vital Signs	Ht: Wt:	BP:				
Patient Health Concerns Address reason for visit Patient-centered approach						
Orientation	Clinic appointments and health sy	vstem				
Health History	Allergies, Current meds					
	Previous Illness		<b>B</b> Immunization status			
Psychosocial Assessment	Past education: Past occupation(s):		Remain alert to possible PTSD but do not routinely screen for history of trauma			
	Current housing:		A If linked to integrate Depression Screen	ed program:		
	Migration/Displacement History:		Document date of refuge	Document date of refugee claimants-hearing		
Education	Nutrition screening & <b>(B)</b> counseling (programs to promote breastfeeding)		Screen for Unmet Contraceptive Needs/ Emergency Contraception			
			A Home visitation for	r high risk mothers (infant <3)		
Physical Exam Important signs in immigrants	Focused examination to address patient's presenting complaint					
from developing countries	Remain alert for malaria <sup>∗</sup> if fever from      M malaria zone					
Problems/Plan	Plan and book follow-up visit					
Screening Investigations	♠ Mantoux Skin Test (TST)*		A Hep B (sag/sab/cab)*	♦ Hep C antibody*		
	<b>⚠</b> CBC with differential (childre	n/females)	Serology for Varicella*	A HIV (A endemic regions)*		
	Serology for Strongyloidias	sis*	♠ Serology for Schistosomiasis*			
Immunizations*	A Children (Age Dependent):		Adults:			
	♠ DPT-aP	·IPV	◆ DPT	♦ Varicella		
1	A MAND A	/aricolla	<b>♦</b> MMR			

: Links to an interactive synopsis of available evidence and recommendations for the condition.

• : Links to the relevant section of the guidelines published in the Canadian Medical Association Journal.

: Links to the recommendations on the map.

Evidence Link: **(4) Bold-CCIRHs Recommendations (3)** Systematic Review Linked Evidence: US and Canadian Task Force Preventive Care.





**Disclaimer:** Given the constantly evolving nature of evidence and changing recommendations, the preventative checklist is meant as a guide only.

Fair Use Authorization: See ccirhken.ca



	2 <sup>nd</sup> Visit (2-7 days)				
	Date:				
Vital Signs	Wt: BP:				
Patient Health Concerns Address reason for visit Patient-centered approach					
Physical Exam Important signs in immigrants from developing countries	Screen Visual Acuity  Nutritional status, fevers, scars/skin lesions, clubbing, wheezes, heart murmurs, lymphadenopathy, organomegaly, limb weakness				
Problems/Plan	NSAIDs for Dental Pain and Refer for Dental pathology/pain				
Screening Investigations	Fasting Glucose (>35)	3 LDL/Cholesterol (men>35, women >45)			
	♠ Chest X-ray if Mantoux test>10 mm* Remain alert for isolation for pregnant				
	Screen for obesity				
	3 <sup>rd</sup> Visit (1-3 months)	Later visits (3-6 months)			
	Date:	Date:			
Vital Signs	Wt: BP:	Wt: BP:			
Patient Health Concerns Address reason for visit Patient-centered approach					
Orientation	Verify links to local resources (ie libraries, local events)				
Psychosocial Assessment	Remain alert for adjustment stress, signs of  child neglect/intimate partner violence	Remain alert for possible onset of depression/ PTSD			
Education	<ul> <li>❖ Diet counseling (Iron Deficiency and Diabetes)</li> <li>❖ Dental Care (tooth brushing)</li> <li>❖ Adequate Vitamin D</li> </ul>	<ul><li>③ Positive Parenting</li><li>③ Exercise</li><li>⑤ Assess for Smoking and Alcohol misuse</li></ul>			
Physical Exam Important signs in immigrants from developing countries	Ensure appropriate clothing for weather (cold and sun)				
Problems and Plan	Refer if positive for Hepatitis B and HIV				
Screening Investigations	♠ Cervical cytology	<b>3</b> Mammography (50-75)			
	Consider testing for chlamydia; GC,	<b>3</b> Fecal Occult Blood (>50)			
	<b>3</b> syphilis (VDRL)	<b>❸</b> Osteoporosis screening (women >65)			
Immunizations	♦ Hepatitis B (non-immune)	♦ HPV vaccination (for 9-25 year old females)			
	♦ Varicella (non-immune)	-			







\*See Resource Page

**Disclaimer:** Given the constantly evolving nature of evidence and changing recommendations, the CCIRH preventative checklist is meant as a guide only.



Design & Production: Centre for e-Learning, Teaching and Learning Support Service (TLSS), University of Ottawa



#### Resource - see http://ccirhken.ca/ for more http://www.ccirhken.ca/ccirh/checklist\_website/en/resources.html

## Tuberculosis Screening: Tuberculin skin test (TST) Indications for TST: persons at high risk for disease

- Contact with contagious TB, immigrants from TB endemic country within 5 years of arrival
- Increased risk of reactivation due to impaired immunity: HIV-AIDS, Diabetes, Renal Failure, Corticosteroids or other immunosuppressant drugs

### INH Treatment of Latent Tuberculosis Infection (active disease ruled out)

Isoniazid 300mg OD (children 5mg/kg); consider pyridoxine 25-50mg OD to prevent neuropathy in malnourished states

- Provide 9 months of INH for all adults
- Consider up to 12 months in children

#### Canadian criteria for a positive TST

#### High risk people: 5mm

HIV, Contact with active TB, signs of inactive TB on CXR, organ transplant steroids >15mg/day

#### High risk conditions: 10 mm

Silicosis, DM, Chronic Renal Failure, Leukemia, lymphoma, Malnutrition, child<5 years of age

#### High Prevalence Population: 10 mm

Foreign Born (high prevalence countries- see Greenaway et al. TB in CMAJ 2011) arrived <5 years, health care worker, aboriginal, prisons, homeless, urban poor

#### \*Risk of INH hepatotoxicity (AST> 5 times normal)

Age Risk
• 25-34 4/1000
• 35-49 8/1000
• 50+ 19/1000

Monitoring (i.e. AST at 3 weeks and Q 3months) is required for those over 50 years of age and those with pre-existing liver disease, alcoholism or concomitant use of hepatotoxic drugs.

**Immunizations**: Needed for primary prevention- particularly for travel to country of origin. If status unknown, serology: Hepatitis B, Varicella and offer a primary series: MMR, TdPP.

**Consider:** Also consider Hepatitis A for all immigrants and refugees and Pneumococcal and H influenza for sickle cell disease

- -92 % of congenital Rubella syndrome in Canada in foreign born (FB) -Large proportion of FB involved in Rubella and Varicella outbreaks
- -Most neonatal Tetanus in the FB
- -WHO Extended Program of Immunization (EPI) program began in 1974- so many FB adults not covered this program does not routinely provide Rubella

## Visiting Friends and Relatives (VFR) Travel- preparation for future travel home (see travel health website: www.TravelHealth.gc.ca)

**Consider**: Fever, Meningococcal, Typhoid vaccines, prophylaxis for malaria. Counseling for Mosquito avoidance, DEET repellent, and bed nets Sex Transmitted Disease and motor vehicle accident prevention: seat belts,

Antibiotics for severe diarrhea (i.e. Azithromycin 1000mg once) Generous supply of regular medication in case trips are extended Summary of health information

#### Laboratory Investigations:

## \*Basic Tenets of Screening: suitable test and facilities to diagnose available, accepted treatment available, recognized latent or asymptomatic disease stage, diagnosis and treatment should be cost effective.

\*Consider **periodic screening** for infectious disease and chronic illness tailored to history of travel and lifestyle

#### Special Laboratory Investigations to Consider

\*Malaria: Rapid Diagnostic Test (RDT), thick & thin smears when fever within 3 months of travel to Malaria zone.

Note: Many cases of Malaria occur in immigrants from developing countries, both on migration or after traveling home

**\*Vitamin D: 25-Hydroxycholecalciferol**: bone and muscle aches in women who use body veils.

#### Working with an interpreter

**Pre-interview**: Discuss with the interpreter the goal of the interview, emphasize confidentiality, and seating arrangements

Interview: Speak to patient not to the interpreter- ensures patient faces physician when interpreter speaks, explain the interpreter's role, and frequently repeat back to patient what you hear.

**End of the interview**: Repeat important concepts, review treatment plan carefully, have patient repeat back general diagnosis and plan

#### Global Health Risks

alcohol moderation

Tuberculosis, Malaria, HIV-AIDS, Hepatitis A, B,C, Typhoid, Measles, Intestinal Parasites, Rheumatic Heart Disease, undiagnosed chronic conditions; Trauma and Violence: Rape, Torture

Malnutrition and Micronutrient deficiency: iron, folate, iodine (some regions), Thalasemias (Africa, Middle East) Sickle cell (Africa, Caribbean); microcytic anemia, replace iron and then do Hgb electrophoresis

#### Treatment of common asymptomatic intestinal worms and parasites

 $^{*}$  Doses are same for children unless noted by asterisk.  $^{**}$  not available in Canada

#### Intestinal worm or parasite **Primary treatment** Alternative treatment Metronidazole 750 tid x 10d Entamoeba histolytica Paramomycin 500 mg po tid×7d\* (positive serology or stool antigen) lodoquinol 650 mg po tid×20d\* Giardia lamblia Metronidazole 250 mg po tid×5d\* Tinidazole Ascaris lumbercoides Albendazole 400 mg po×1 dose<sup>6</sup> Mebendazole 100mg bidx3d Enterobius vermicularis Albendazole 400 mg po×1 dose (repeat in 2wks)6 Mebendazole 100mg once then repeat in 2wks Strongyloides stercoralis Thiabendazole 50 mg/kgdivided bid×2d Albendazole/Ivermectin (max dose 3 g/d) \* Schistomsoma mansoni, haematobium Praziquatel 40mg/kg po divided bid x 1d Trichuris trichiura Albendazole 400 mg po×1 dose Mebendazole 100mg tid x3d

Resources: 1. Online eligibility check for IFHP for refugee claimant patients https://provider.medavie.bluecross.ca/

- 2. Children and Youth to Canada: A Health Care Guide, Canadian Pediatric Society, 2000 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1987659/
- 3. Canadian Guide to Immunizations, Health Canada, 2002 http://www.phac-aspc.gc.ca/publicat/cig-gci/index-eng.php
- 4. Travel and Tropical Medicine, Public Health Agency of Canada http://www.TravelHealth.gc.ca
- 5. Life expectancy calculator, PHIRN, 2012 http://www.rrasp-phirn.ca/risktools
- 6. Health Canada's Special Access Programme: Drugs and health products [database] Ottawa (ON): Health Canada; 2008 Available: http://www.hc-sc.gc.ca/dhp-mps/acces/drugs-drogues/index-eng.php
- 7. Additional resources and information for clinicians, Bridge Refugee Clinic, Vancouver Coastal Health: www.refugeehealth.ca









